Revenue
2022
2023
2024
2025
Scinai Immunotherapeutics Ltd. (SCNI)
Price$1.96Cached quote
Net income
2017
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2016
2017
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $389 | $0 | $0 | — | — | — | — | — | — | — |
| Gross profit | −$2.7M | −$580,000 | $0 | $0 | — | — | — | — | — | — | — |
| Gross margin | −202.29% | −149,100.26% | — | — | — | — | — | — | — | — | — |
| Research & development | $2.4M | $5.5M | $5.2M | $5.8M | $3.3M | $16.0M | — | — | $5.4M | — | — |
| Operating expenses | $4.9M | $8.1M | $9.7M | $11.1M | $10.9M | — | — | — | $6.8M | — | — |
| Operating income | −$7.5M | −$8.6M | −$9.7M | −$11.1M | −$10.9M | — | — | — | — | — | — |
| Operating margin | −575.29% | −2,220,565.55% | — | — | — | — | — | — | — | — | — |
| EBITDA | −$6.1M | −$7.0M | −$9.2M | −$10.5M | −$10.4M | — | — | — | — | — | — |
| EBITDA margin | −466.90% | −1,796,658.10% | — | — | — | — | — | — | — | — | — |
| Net income | −$8.3M | $4.8M | −$6.5M | −$5.8M | −$12.9M | −$1.4M | — | — | −$10.0M | — | — |
| Net profit margin | −633.64% | 1,232,904.88% | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | $0.00 | $0.00 | $0.00 | $0.01 | -$0.02 | — | — | — | -$0.05 | — | — |
| Diluted EPSper diluted share | $0.00 | $0.00 | $0.00 | $0.01 | -$0.02 | — | — | — | -$0.05 | — | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Reichman Amir | 711.64M |
Mark Elad | 160.36M |
GERMAIN MARK | 120M |
Ben-Or Uri | 33.33M |
CITADEL ADVISORS LLC | 62.26K |
ARMISTICE CAPITAL, LLC | 35.94K |
Virtu Financial LLC | 19.49K |
XTX Topco Ltd | 16.76K |
RHUMBLINE ADVISERS | 13.51K |
StoneX Group Inc. | 13.09K |
HRT FINANCIAL LP | 12.09K |
CAPTRUST FINANCIAL ADVISORS | 12.04K |
UBS Group AG | 3.96K |
ROYAL BANK OF CANADA | 815 |
MORGAN STANLEY | 58 |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data